BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on Maxipime® (cefepime): risk of serious neurologic adverse events in patients with renal impairment

Active substance: cefepime

Information is circulated on the risk of serious adverse events, including encephalopathy, in patients with renal impairment who received doses that exceeded the recommendations.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 178KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK